KRAS and cancer: In contrast, the HotLow subgroup retained enrichment of IFN-γ/IFN-α response and allograft rejection, but with lower normalized enriched score (NES) values, and additionally showed estrogen response and KRAS signaling, reflecting partial immune activation together with cancer cell-intrinsic pathways.